All In Biotech

Drug Trial Radar · NCT02720367

Safety and Tolerability of TAR-200 mg in Subjects With Non-Muscle-Invasive Bladder Cancer

A Phase 1b, Multicenter, Open Label Study Evaluating Safety, Tolerability and Preliminary Efficacy of GemRIS 225 mg in Subjects With Non-Muscle-Invasive Urothelial Carcinoma of the Bladder

Last checked: Nov 19, 2026Latest source record: Mar 10, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

12

Actual

Start

Jan 2016

Primary completion

Jan 2018

Study completion Mar 2020

Sponsor

Lead sponsor
Taris Biomedical LLCIndustry
Sponsor type
Industry
First posted
Mar 25, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if TAR-200, an investigational drug-delivery system is safe and tolerable in patients with recurrent low or intermediate risk non-muscle-invasive bladder cancer (NMIBC) between diagnosis and transurethral resection of bladder tumors (TURBT)

Conditions

  • Urinary Bladder Cancer

Interventions

  • Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200Drug

    TAR-200 is a passive, nonresorbable gemcitabine-releasing intravesical system whose primary mode of action is the controlled release of gemcitabine into the bladder over an indwelling period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety as defined by the number of participants with treatment emergent adverse events (TEAEs) coded with MedDRA and graded for severity with CTCAE v4.0Time frame: From the point of signing the informed consent form through last study visit, up to 59 days.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Canisius Wilhelmina Ziekenhuis

    Nijmegen, Netherlands

  • Radboudumc

    Nijmegen, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.